Summary of NIH Guidelines for Recombinant DNA & Synthetic Nucleic Acids
|
|
- Jody Garrison
- 7 years ago
- Views:
Transcription
1 Summary of NIH Guidelines for Recombinant DNA & Synthetic Nucleic Acids The National Institutes of Health (NIH) Guidelines for Research Involving Recombinant Synthetic Nucleic Acid Molecules (recombinant or synthetic nucleic acids NIH Guidelines) are published by the Office of Biotechnology Activities (OBA). The NIH Guidelines outline the scope of experiments involving recombinant or synthetic nucleic acid molecules and the required containment levels for each category of experiment for the safe conduct of research. The NIH Guidelines are amended periodically to ensure protection of the workers handling recombinant or synthetic nucleic acid molecules, and also to protect public health and the environment, and that adequate containment is in place. The most recent copy of the NIH Guidelines can also be accessed at the NIH OBA website at: Recombinant and synthetic nucleic acid molecules are defined as: Molecules that are constructed by joining nucleic acid molecules and can replicate in a living cell, i.e. recombinant nucleic acids; Nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e. synthetic nucleic acids; or Molecules that result from the replication of those described above. The NIH Guidelines apply to research that is conducted at or sponsored by an institution that receives NIH funding for research with recombinant or synthetic nucleic acids or institutions that receive funding for molecular biology experiments. Institutions that receive funding from the NIH must ensure full conformity with the NIH Guidelines for all experiments conducted at the institution regardless of funding source. Failure to comply with the NIH Guidelines can lead to a loss of NIH funding for recombinant DNA Research and could ultimately result in suspension of NIH research funding awarded to the institution until corrective measures have been established. Key responsibilities for the institution receiving NIH funding for research with recombinant or synthetic nucleic acids include: Establish an Institutional Biosafety Committee (IBC); Appoint an IBC Chair to lead the periodic IBC meetings; Designate a Biological Safety Officer (BSO) when high risk or large scale experiments are conducted; Ensure adequate expertise for the review of recombinant or synthetic nucleic acids protocols involving plants, animals and human gene transfer experiments; Periodically inspect laboratories to ensure that the facility, work practices and other requirements conform with the NIH Guidelines; Train IBC members, the BSO, Principal Investigators, and laboratory staff; Develop a health surveillance program for researchers conducting high risk and large scale experiments; Develop emergency response plans for addressing spills, exposures, laboratory acquired infections, containment breaches, and violations; File an annual update of the IBC roster with biosketches to the NIH; and Report significant exposures, accidents, loss of containment or release of recombinant materials to OBA. The Institutional Biosafety Committee
2 The Institutional Biosafety Committee (IBC) should be established and supported by the highest administrator at the institution. The IBC should have oversight for potentially hazardous work and does not have to be limited to experiments involving recombinant or synthetic nucleic acids. IBCs set the policy for the safe conduct of biohazard research and oversee all experiments involving recombinant or synthetic nucleic acids projects conducted at the institution. IBCs must ensure compliance with the NIH Guidelines throughout the entity at NIH funded institutions. All investigators at an institution that receives NIH funding must comply with the NIH Guidelines regardless of funding source. This is an important point for an institution as compliance with the NIH Guidelines extends to each and every one of their laboratories. All work must be conducted in compliance with the NIH Guidelines. Responsibilities of the Institutional Biosafety Committee (IBC) include the requirement to retain a minimum of 5 members, at least 2 of which must be from the community and not affiliated with the institution. Members should be appointed by the institution's senior responsible official and reviewed annually. It is recommended that IBC members have a set term limit, to ensure a rotation of new members onto the committee at periodic intervals. Members may not participate in the review or approval of any of their own protocols or those in which they hold a financial or other interest. Institutions should have a conflict of interest policy to ensure that this policy is followed. The IBC must also have expertise in molecular biology and recombinant or synthetic nucleic acids technology; human, animal and plant pathogens; biosafety, occupational health and medical surveillance; physical and biological containment; and legal guidance where applicable. IBC membership should include varied disciplines, from recombinant or synthetic nucleic acids and molecular biology, microbiology, laboratory safety, engineering, and representation from the laboratory technical staff. IBC members with plant and animal containment expertise must be available if research involves plants, animals or plant and animal pathogens. IBCs should not be limited to its membership in the review of recombinant or synthetic nucleic acids protocols as the institution should have access to other faculty with expertise when needed. Other experts within the institution and even those outside the institution should be contacted for assistance if needed in the review of recombinant or synthetic nucleic acids research in a non-voting capacity. IBCs can also review experiments with infectious agents, toxins and other biohazards, as they are not limited to only recombinant or synthetic nucleic acids experiments. The IBC must review the PIs written risk assessment and site-specific safety procedures. The PI's written risk assessment should include a proposal for physical and biological containment levels in accordance with the NIH guidelines when registering work with the IBC. The PI must also submit a registration document that contains specific information regarding their proposed non-exempt recombinant or synthetic nucleic acids experiment. The IBC must perform an independent risk assessment and is responsible for setting the containment level for the experiment. The IBC has responsibility for ensuring that Principal Investigators have trained personnel. Retraining should be provided periodically. Although not specified, retraining should be frequent enough to ensure that PIs maintain awareness of their responsibilities under the NIH Guidelines. Inspections of proposed work practices and facilities should also be periodically monitored and documented. IBCs should also develop a policy for sanctions in advance and communicate this to the PIs at their institution. Related institutional entities, such as the Dean's Office, Department Chairs, or Institutional Officials, should be involved in the development of a sanction policy. Securing the support of the administration is integral to an effective program. As non-conformity can involve a multitude of factors, each incident should be evaluated on a case by case basis. IBCs should work with their PIs
3 after each incident to prevent a repeat occurrence of the event. Incidents should be documented, filed and reported to required authorities. In addition to the NIH OBA, the IBC should establish formal relationships with related Committees and groups within and outside their institution, such as the Institutional Review Board (IRB) and the Institutional Animal Care and Use Committee (IACUC). Within an institution, the IBC should have cross representation with the IACUC and the IRB. Problems with the NIH Guidelines identified by the BSO are reported to the IBC. The BSO also advises on laboratory security and assists with the development of emergency response plans. To summarize, the official duties of the BSO under the NIH Guidelines are to: Conduct periodic inspections to ensure that laboratory standards are followed; Report to the IBC any significant problems, violations of the NIH Guidelines, and any significant research-related accidents and illnesses; Develop emergency response plans for handling accidental spills and personal contamination; Investigate laboratory accidents involving recombinant or synthetic nucleic acids and assist with remediation and mitigation measures; Provide advice on laboratory security; and Provide technical advice to PIs and the IBC on research safety procedures. Principal Investigators conducting recombinant or synthetic nucleic acids experiments are responsible for full compliance with the NIH Guidelines. They make the initial NIH recombinant or synthetic nucleic acids classification and determination of containment for their experiments at time of registration. PI's are also responsible for instructing and training researchers in laboratory techniques and safe working procedures and for oversight of the safety performance for the researchers they supervise. The PI cannot begin or modify any non-exempt recombinant or synthetic nucleic acids experiments without approval or in some cases registration by the IBC. The PI must also report violations of the NIH Guidelines and serious recombinant or synthetic nucleic acids incidents to the NIH OBA within 30 days. PIs must conduct a formal risk assessment for their studies. The NIH Guidelines provides assistance with risk assessment in Section II of the NIH Guidelines. Detailed information on Risk Assessment was provided in an earlier Module in the Biosafety Series entitled Biohazard Risk Assessment. PIs are also responsible for selecting the appropriate classification within the NIH Guidelines of their proposed experiments. Section III of the NIH Guidelines describes experiments that require registration, review, and approval before initiation. A summary of the NIH Guidelines Section III is provided below. Section III-A-1 (Major Action) Cloning a therapeutic antibiotic resistance gene into a human, animal, or plant pathogen is a major action, if the transfer could compromise the ability to treat or control the disease if the resistance is not acquired naturally (these experiments must be reviewed by the NIH Recombinant DNA Advisory Committee (RAC) and approved by the NIH Director). Section III-B-1 This section is related to the cloning of DNA encoding for a low LD50 toxin or work with vectors that
4 express toxins with a low LD50 (< 100 nanograms per Kilogram body weight). These experiments must be registered with and approved by the NIH RAC. Botulinum and tetanus toxin are examples of toxins that have LD50's below 100 nanograms per Kilogram of body weight. The cloning of toxins with an LD50 < 100 micrograms per Kilogram body weight must also be reviewed and approved by the IBC. This section also includes experiments that have already been approved as a III-A-1-a Major Action under the NIH Guidelines if the exact experiment is proposed at a new institution. This experiments may not be initiated until approved by the IBC and reviewed by the NIH. Section III-C-1 Human gene transfer research experiments: the deliberate transfer or recombinant or synthetic nucleic acids, or DNA or RNA derived from recombinant or synthetic nucleic acids, into one or more human research participants. These experiments include the transfer of DNA with defective viral vectors, such as retroviral, adenoviral and Lentiviral vectors, along with the use of liposomes and other methods of delivery. These experiments require registration with the NIH OBA and also preapproval from the Institutional Review Board and the U.S. Food and Drug Administration prior to initiation. Section III-D Section III-D experiments comprise the bulk of the experiments reviewed by the IBC and include the use of Risk Group 2 through 4 agents and restricted pathogens, or defective pathogens in cell culture, animals, plants, arthropods, and large scale experiments (work with > 10 liters of recombinant or synthetic nucleic acids culture). Examples of III-D Experiments Cloning a gene into a pathogen Use of a pathogen as a vector or expressing a pathogen into a lower prokaryotic or lower eukaryotic cell Using a defective pathogen vector with or without helper virus in cell culture or animal experiments Experiments involving toxins, pathogens, defective vectors, and other genetically materials used in animals, plants or arthropods. Section III-E Section III-E experiments are a category of research that allow the PI to initiate the work at the time of submission of a recombinant or synthetic nucleic acids registration form to the IBC. The protocol must still be reviewed by the IBC and any new information from the review must be provided to the PI following the IBC meeting. Examples of III-E experiments include: Research that involves less than 2/3 of the genome of Risk Group 2 agents; (Experiments involving Risk Group 3 or 4 pathogens or from restricted agents are not included) The creation or production of transgenic rodents requiring BSL1 containment; and Work with whole plants that involve the use of noxious weeds, non-exotic agents, and exotic agents that won't threaten the ecosystem are also included as III-E experiments. Exempt experiments (represent recombinant or synthetic nucleic acids research that does not pose a
5 significant risk and do not require review and registration by the IBC) are described in Section III-F of the NIH Guidelines. Examples of exempt research includes: Those recombinant or synthetic nucleic acids experiments that are not in organisms or viruses; PCR; The use of known exchangers, recombinant or synthetic nucleic acids from a host organism propagated in the same host; and Those recombinant or synthetic nucleic acids experiments that do not pose a significant risk to health or the environment. Appendix C details exempt experiments that do not pose a risk to the public and include research that involves less than 50% of the genome from a Risk Group 2 pathogen, experiments using E. coli, B. subtilis, or S. cerevisiae, and the purchase or transfer of transgenic rodents. The generation of transgenic rodents by breeding to create a new strain shall be EXEMPT from the NIH Guidelines if the following criteria are met. Both parental rodents can be housed under BSL1 containment; AND Neither parental transgenic rodent contains the following genetic modifications: o Incorporation of more than 50% of the genome of an exogenous eukaryotic virus from a single family of viruses; OR o Incorporation of a transgene that is under the control of a gammaretroviral long terminal repeat (LTR); AND o The transgenic rodent that results from this breeding is not expected to contain more than 50% of an exogenous viral genome from a single family of viruses. This exemption DOES NOT pertain to other transgenic animals such as zebrafish, drosophila, rabbits, pigs, etc. It also DOES NOT pertain to transgenic experiments involving plants. IBC Meetings IBC meetings must be conducted in a manner that allows interaction between committee members either in person or through a conference call. Attendance must be taken at IBC meetings to ensure that a meeting quorum has been attained. IBC meetings are encouraged to be open to the public and institutions are urged to post information regarding their meeting schedules. Minutes of IBC meetings must be filed and made available to the NIH OBA and the public upon request. IBC minutes should include the following information: Date and place of the IBC meeting Record that prior minutes were approved Individuals in attendance Opening and closing times of the meeting All major motions Major points that were approved Time of the meeting opening and adjournment Sufficient detail to record key discussion and the rationale for any decisions made (this should include a review of the PIs risk assessment and detail the following): o Agent characteristics o Type of manipulations planned
6 Incident Reports o Source of the inserted DNA sequences o Nature of the inserted DNA sequences o Host(s) and vector(s) to be used o Whether an attempt will be made to obtain expression of a foreign gene and the protein that will be produced o Containment conditions to be implemented o Section of the NIH Guidelines applicable to the proposed work Significant incidents, violations and research-related accidents and illnesses must be reported to the NIH OBA within 30 days or immediately in the event of personal exposures. Spills or accidents in BSL2 laboratories resulting in overt exposure must be immediately reported to NIH OBA and the IBC. Spills or accidents occurring in high containment laboratories resulting in an overt or potential exposure must be immediately reported to NIH OBA, the IBC and the BSO. Although PIs are responsible for reporting incidents, the institution, IBC and BSO may also report the incident to the NIH OBA. Types of Incidents that Must be Reported Spills, or accidents in BSL2 laboratories resulting in overt exposure must be immediately reported to the NIH OBA Spills, or accidents resulting in overt or potential exposure in BSL3 and BSL4 must be immediately reported to the NIH OBA Personal injury involving recombinant or synthetic nucleic acid molecules Illness potentially associated with recombinant or synthetic nucleic acids research Breach of containment associated with recombinant or synthetic nucleic acids molecules (i.e. a spill of BSL2 or higher recombinant or synthetic nucleic acids outside of primary containment) Improperly discarded recombinant or synthetic nucleic acid waste materials Incident reports to NIH OBA should include the nature and consequences of the incident, the cause of the incident, and a detailed report of the response measures taken by the institution. Appendices of the NIH Guidelines The NIH Guidelines also contain appendices to assist IBCs in their review of recombinant or synthetic nucleic acids protocols. Appendix B contains the "Classification of Etiologic Agents on the Basis of Hazard," which lists human pathogens by risk group Appendix G provides containment requirements for cell culture and small animal experiments and outline appropriate work practices, safety equipment, and facility design for each biocontainment level (BSL1 through BSL4) Appendix K provides containment requirements for large scale recombinant or synthetic nucleic acid experiments (> 10 liters of culture) Appendix M details the requirements for human gene transfer experiments.
7 Appendix P provides containment requirements for recombinant or synthetic nucleic acid experiments involving transgenic plants Appendix Q provides containment requirements for recombinant or synthetic nucleic acid experiments involving large animals
Texas Tech University Health Sciences Center. Recombinant DNA Biosafety Committee (RDBC) POLICIES AND PROCEDURES MANUAL. Effective Date: May 15, 2013
Texas Tech University Health Sciences Center Recombinant DNA Biosafety Committee (RDBC) POLICIES AND PROCEDURES MANUAL Effective Date: May 15, 2013-1 - 1.0 Introduction This Texas Tech University Health
More informationPOLICIES AND PROCEDURES FOR THE HOWARD UNIVERSITY INSTITUTIONAL BIOSAFETY COMMITTEE (IBC)
June 2013 POLICIES AND PROCEDURES FOR THE HOWARD UNIVERSITY INSTITUTIONAL BIOSAFETY COMMITTEE (IBC) Page 1 of 19 CONTENTS SECTION 1: PURPOSE AND SCOPE OF POLICIES AND PROCEDURES --------------------------------
More informationCarnegie Mellon University s Policy and Procedures for Recombinant and Synthetic Nucleic Acid Materials Spills
Carnegie Mellon University s Policy and Procedures for Recombinant and Synthetic Nucleic Acid Materials Spills Background In accordance with Section IV-B-2-b-(6) of the NIH Guidelines for Research Involving
More informationBiological Agent Registration Application
Biological Agent Registration Application T h i s a p p l i c a t i o n m u s t b e c o m p l e t e d b y t h e P r i n c i p a l In v e s t i g a t o r ( P I ) a n d m u s t b e approved by the Biological
More informationUC Irvine Environmental Health & Safety SECTION: 2.07 INITIATOR: Campus Biosafety Officer
UC Irvine Environmental Health & Safety SECTION: 2.07 INITIATOR: Campus Biosafety Officer TITLE: Institutional Biosafety Committee REVISION DATE : 03/16/2016 1. Program Description 2. Mission, Purpose,
More informationAdministrative Procedure Chapter 12, Research Administrative Procedure: AP 12.217, Procedure for Institutional Oversight of Life
Administrative Procedure, AP 12.217 Procedure for Institutional Oversight of Life Sciences Dual Use Research of Concern Page 1 of 15 Administrative Procedure Chapter 12, Research Administrative Procedure:
More informationUniversity of Nevada, Reno Environmental Health and Safety Policy
University of Nevada, Reno Environmental Health and Safety Policy Title: Institutional Oversight of Dual Use Research of Concern Date: September 24, 2015 Revision: 0 Page: Page 1 of 7 POLICY: The University
More informationCaltech Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern
Caltech Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern Purpose The purpose of this Policy is to strengthen regular institutional review and oversight of certain life sciences
More informationSection VI Principles of Laboratory Biosecurity
Section VI Principles of Laboratory Biosecurity Since the publication of the 4th edition of BMBL in 1999, significant events have brought national and international scrutiny to the area of laboratory security.
More informationBIOSAFETY POLICY. Vice-President, Services PURPOSE
Effective Date: March 4, 2016 Supersedes/Amends: May 2006 Originating Office: Office of the Vice-President, Services Policy Number: VPS-52 PURPOSE Biological materials have the potential, if not managed
More informationNIH POLICY MANUAL. 1340 - NIH Occupational Safety and Health Management Issuing Office: ORS/DOHS 301-496-2960 Release Date: 2/27/06
NIH POLICY MANUAL 1340 - NIH Occupational Safety and Health Management Issuing Office: ORS/DOHS 301-496-2960 Release Date: 2/27/06 1. Explanation of Material Transmitted: This chapter establishes the scope
More informationResponsibilities of the Biosafety Professional and Institution
Responsibilities of the Biosafety Professional and Institution Debra L. Hunt, DrPH, CBSP Director, Biological Safety; Responsible Official (Select Agents) Assistant Professor Duke University / Duke Medicine
More informationRecombinant DNA and Biotechnology
Recombinant DNA and Biotechnology Chapter 18 Lecture Objectives What Is Recombinant DNA? How Are New Genes Inserted into Cells? What Sources of DNA Are Used in Cloning? What Other Tools Are Used to Study
More informationCHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA
CHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA INTRODUCTION DNA : DNA is deoxyribose nucleic acid. It is made up of a base consisting of sugar, phosphate and one nitrogen base.the
More informationINDEPENDENT LEARNER. Series Guide
INDEPENDENT LEARNER Series Guide CITI Program s independent learner courses are intended to provide access to individuals not affiliated with a subscribing organization or those who have special content
More informationBiosafety Level 3 Program Manual
Biosafety Level 3 Program Manual Biosafety 3 Manual Table of Contents 1.0 Introduction... 1 2.0 Objective... 2 3.0 Applicability... 3 4.0 Definitions... 3 5.0 BSL-3 Personnel... 5 6.0 Elements of the BSL-3
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE QUALITY OF BIOTECHNOLOGICAL PRODUCTS: ANALYSIS
More informationRequired Biosafety Level Three (BSL-3) Practices, Procedures, Facilities, and Safety Equipment For BSL-3 and BSL3/2 Laboratories
Required Biosafety Level Three (BSL-3) Practices, Procedures, Facilities, and Safety Equipment For BSL-3 and BSL3/2 Laboratories 1) LABORATORY OPERATIONS a) Responsibilities: A clear organization is set
More informationBiohazardous Waste Management Plan
Central Michigan University Biohazardous Waste Management Plan This document has been prepared to provide guidance to Central Michigan University (CMU) employees in the use and disposal of biohazardous
More informationFREQUENTLY ASKED QUESTIONS
NATIONAL SCIENCE ADVISORY BOARD FOR BIOSECURITY FREQUENTLY ASKED QUESTIONS Establishment of the NSABB 1. What is the Administration s policy on biosecurity in life sciences research? 2. Why was the NSABB
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationFacility Safety Plan State University of New York Upstate Medical University
Facility Safety Plan State University of New York Upstate Medical University A. Research Operations / Standard Operating Procedure The State University of New York Upstate Medical University maintains
More informationEuropean Medicines Agency
European Medicines Agency July 1996 CPMP/ICH/139/95 ICH Topic Q 5 B Quality of Biotechnological Products: Analysis of the Expression Construct in Cell Lines Used for Production of r-dna Derived Protein
More informationUnited States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern
United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern Contents Section 1. Introduction... 2 Section 2. Purpose... 4 Section 3. Guiding Principles for
More information7- Master s Degree in Public Health and Public Health Sciences (Majoring Microbiology)
7- Master s Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 38 credit hours: 1- Basic requirements: 10 credit hours. 150701, 150702, 150703,
More informationTransfection-Transfer of non-viral genetic material into eukaryotic cells. Infection/ Transduction- Transfer of viral genetic material into cells.
Transfection Key words: Transient transfection, Stable transfection, transfection methods, vector, plasmid, origin of replication, reporter gene/ protein, cloning site, promoter and enhancer, signal peptide,
More informationFACILITY SAFETY PLAN INSTRUCTIONS
FACILITY SAFETY PLAN INSTRUCTIONS Approval of the Facility Safety Plan is granted on an institution basis rather than on a proposal basis. Facility Safety Plan approvals are granted for a 5-year period
More informationCanadian Public Health Laboratory Network. Core Functions of Canadian Public Health Laboratories
Canadian Public Health Laboratory Network Core Functions of Canadian Public Health Laboratories Canadian Public Health Laboratory Network The CPHLN Core Functions of Canadian Public Health Laboratories
More informationBiotechnology: DNA Technology & Genomics
Chapter 20. Biotechnology: DNA Technology & Genomics 2003-2004 The BIG Questions How can we use our knowledge of DNA to: diagnose disease or defect? cure disease or defect? change/improve organisms? What
More informationBiosafety Spill Response Guide
Yale University Office of Environmental Health & Safety Biosafety Spill Response Guide Office of Environmental Health & Safety 135 College Street, 1 st Floor, New Haven, CT 06510 Telephone: 203-785-3550
More informationUCLA Policy 811: Environmental Health and Safety
UCLA Policy 811: Environmental Health and Safety Issuing Officer: Assistant Vice Chancellor, General Services Responsible Dept: Environment, Health & Safety Effective Date: September 5, 2007 Supersedes:
More informationSection III Principles of Biosafety
Section III Principles of Biosafety A fundamental objective of any biosafety program is the containment of potentially harmful biological agents. The term containment is used in describing safe methods,
More informationAdeno-Associated Viral Vectors
Adeno-Associated Viral Vectors Background Adeno-associated viruses (AAV) are single strand DNA viruses that require a helper virus (typically adenovirus, herpesvirus and vaccinia) to replicate. When there
More informationClarkson University Environmental Health & Safety Program Overview
Clarkson University Environmental Health & Safety Program Overview Mission Clarkson University is committed to maintaining a safe living, learning, and working environment and to furnishing a workplace
More informationCCR Biology - Chapter 9 Practice Test - Summer 2012
Name: Class: Date: CCR Biology - Chapter 9 Practice Test - Summer 2012 Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Genetic engineering is possible
More informationEdith Cowan University Faculty of Health, Engineering and Science Work Health and Safety Committee
PROCEDURES Title: PROCEDURES - HANDLING INFECTIOUS MATERIALS AND INFECTION CONTROL Descriptors: 1) 2) 3) 4) Category: OS&H Purpose Organisational Scope Policy Statement Definitions Principles Content References
More informationCambridge Biosafety Committee POLICIES AND PROCEDURES
Section 1.00 Introduction Pursuant to Cambridge Municipal Code Recombinant DNA Technology Chapter 8.20.040(A) (the rdna Technology Ordinance ) and the Cambridge Public Health Department s Biosafety Regulation
More informationSafe Operating Procedure
Safe Operating Procedure (Revised 12/11) SPILL AND EXPOSURE RESPONSE FOR BIOHAZARDOUS MATERIALS (INCLUDING RECOMBINANT NUCLEIC ACIDS) (For assistance, please contact EHS at (402) 472-4925, or visit our
More informationRecombinant DNA & Genetic Engineering. Tools for Genetic Manipulation
Recombinant DNA & Genetic Engineering g Genetic Manipulation: Tools Kathleen Hill Associate Professor Department of Biology The University of Western Ontario Tools for Genetic Manipulation DNA, RNA, cdna
More informationCore Functions and Capabilities. Laboratory Services
Core Functions and Capabilities British Columbia Centre for Disease Control Laboratory Services Understanding the role and value of British Columbia s public health laboratory in protecting our community
More informationChapter 23 Definitions of GMO/LMO and modern biotechnology. Three different definitions but the same legal interpretation?
Chapter 23 Definitions of GMO/LMO and modern biotechnology JAN HUSBY NORWEGIAN INSTITUTE OF GENE ECOLOGY (GENØK), TROMSØ, NORWAY Three different definitions but the same legal interpretation? There are
More informationGuidance. 2. Definitions. 1. Introduction
Work with naked DNA or RNA (including oligonucleotides, sirna, mirna, sequences that code for highly biologically active molecules and full length viral genomes) Guidance 1. Introduction The following
More informationCarnegie Mellon University. Institutional Biological Safety Committee SAFETY PLAN FOR THE USE OF BIOLOGICAL MATERIALS AND ASSOCIATED DEVICES
Carnegie Mellon University Institutional Biological Safety Committee SAFETY PLAN FOR THE USE OF BIOLOGICAL MATERIALS AND ASSOCIATED DEVICES Table of Contents 1.0 Introduction 2.0 Program Administration
More informationBiotechnology and Recombinant DNA (Chapter 9) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College
Biotechnology and Recombinant DNA (Chapter 9) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Primary Source for figures and content: Eastern Campus Tortora, G.J. Microbiology
More informationStructure and Function of DNA
Structure and Function of DNA DNA and RNA Structure DNA and RNA are nucleic acids. They consist of chemical units called nucleotides. The nucleotides are joined by a sugar-phosphate backbone. The four
More informationPRINCIPAL INVESTIGATOR REGISTRATION FOR SELECT AGENTS
Page 1 of 5 PRINCIPAL INVESTIGATOR REGISTRATION FOR SELECT AGENTS In order to gain approval by the CDC for use of select biological agents the CDC requires, as part of their application procedure (Sections
More informationScott & White Institutional Biosafety Committee Compliance Program Biohazardous Material Spill Clean-Up Procedure Policy #IBC.002
I. Purpose Biohazardous material usage on the Scott & White campus is regulated by the Scott & White Institutional Biosafety Committee (IBC). Those investigators choosing to perform research with biohazardous
More informationGUIDELINES FOR MANAGEMENT AND HANDLING OF SPENT MYCELIUM FROM BULK DRUG INDUSTRY
GUIDELINES FOR MANAGEMENT AND HANDLING OF SPENT MYCELIUM FROM BULK DRUG INDUSTRY MAHARASHTRA POLLUTION CONTROL BOARD Kalpataru Point, Sion (E), Mumbai 400 022. E-mail : mpcb@vsnl.net Web site : http://mpcb.mah.nic.in
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationNon-Clinical Data/ Materials Distribution Agreement
Non-Clinical Data/ Materials Distribution Agreement The undersigned parties hereby enter into this Non-Clinical Data/ Materials Distribution Agreement as of the date specified on the final page hereof.
More informationThe following standard practices, safety equipment, and facility requirements apply to BSL-1:
Section IV Laboratory Biosafety Level Criteria The essential elements of the four biosafety levels for activities involving infectious microorganisms and laboratory animals are summarized in Table 1 of
More informationBOSTON UNIVERSITY Dual Use Research of Concern ( DURC ) Policy
1. Purpose BOSTON UNIVERSITY Dual Use Research of Concern ( DURC ) Policy The purpose of this policy is to outline Boston University s ( BU ) institutional oversight of Dual Use Research of Concern according
More informationAppendix 2 Molecular Biology Core Curriculum. Websites and Other Resources
Appendix 2 Molecular Biology Core Curriculum Websites and Other Resources Chapter 1 - The Molecular Basis of Cancer 1. Inside Cancer http://www.insidecancer.org/ From the Dolan DNA Learning Center Cold
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationUNIVERSITY OF MAINE POLICIES AND PROCEDURES FOR THE HUMANE CARE AND USE OF ANIMALS
UNIVERSITY OF MAINE POLICIES AND PROCEDURES FOR THE HUMANE CARE AND USE OF ANIMALS University of Maine Office of the Vice President for Research Alumni Hall Orono, ME 04469-5703 581-1498 Effective 7/17/1990
More informationEvaluation Instrument for Accreditation January 1, 2015
Evaluation Instrument for Accreditation January 1, 2015 Copyright 2002-2014 AAHRPP. All rights reserved. Use of the Evaluation Instrument for Accreditation The Evaluation Instrument for Accreditation is
More informationHow To Set Up A National Biological Laboratory Safety And Security Monitoring Program
Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science Volume 10, Number 4, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/bsp.2012.0054 Establishing a National Biological Laboratory Safety
More information7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)
7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,
More informationProcedure for Visitors in UIC Laboratories
Procedure for Visitors in UIC Laboratories 1129 S. Hermitage, Chicago, IL 60612-7217 Office: (312) 996-7411 OBJECTIVE In order to protect the Principal Investigator (PI) and the University of Illinois
More informationPI s Name Date Bldg./Rm# CDC Biosafety Level 3 (BSL-3)
PI s Name Date Bldg./Rm# CDC Biosafety Level 3 (BSL-3) Yes No 1. Is access to the laboratory limited or restricted at the discretion of the laboratory director when experiments are in progress? Yes No
More informationUNIVERSITY OF MIAMI OFFICE OF ENVIRONMENTAL HEALTH AND SAFETY (EHS) BIOLOGICAL AGENTS REGISTRATION FORM
UNIVERSITY OF MIAMI OFFICE OF ENVIRONMENTAL HEALTH AND SAFETY (EHS) BIOLOGICAL AGENTS REGISTRATION FORM This form must be completed by all Principal Investigators or Designee annually or whenever information
More informationThe Johns Hopkins Hospital and The Johns Hopkins University Health, Safety and Environment Manual Biological Safety:
Page 1 of 7 Keywords: Table of Contents Page Number I. POLICY 1 II. SUMMARY 1 III. REVIEW CYCLE 7 Appendix A: Process for Institutional Review of Life Sciences Research within the Scope of the Click Here
More informationA Comparison. Safety and Health Management Systems and Joint Commission Standards. Sources for Comparison
and Standards A Comparison The organizational culture, principles, methods, and tools for creating safety are the same, regardless of the population whose safety is the focus. The. 2012. Improving Patient
More informationUniversity of Notre Dame Laboratory Integrated Safety Plan (ISP)
University of Notre Dame Laboratory Integrated Safety Plan (ISP) I. Executive Summary II. Definitions III. Background and Overview IV. Who is Required to Participate in the Laboratory ISP? V. Benefits
More informationInjury and Illness Prevention Plan (IIPP) University of Nebraska-Lincoln
Environmental Health and Safety Injury and Illness Prevention Plan (IIPP) University of Nebraska-Lincoln Revised March 2011 UNL Environmental Health and Safety 3630 East Campus Loop Lincoln, Nebraska 68583-0824
More informationAnimal Pharming: The Industrialization of Transgenic Animals December 1999
Animal Pharming: The Industrialization of Transgenic Animals December 1999 Animal pharming, the process of using transgenic animals to produce human drugs, is staking its claim in a lucrative world market.
More informationTHE UNIVERSITY OF MAINE BIOMEDICAL WASTE MANAGEMENT PLAN
THE UNIVERSITY OF MAINE BIOMEDICAL WASTE MANAGEMENT PLAN Department: The University of Maine Safety and Environmental Management Department Page i TABLE OF CONTENTS Section Title Page 1. Purpose... 1 2.
More informationBSL 1 Laboratory Biosafety Manual
BSL 1 Laboratory Biosafety Manual Version 1.0 Idaho State University, Office for Research Institutional Biosafety Committee (IBC) 1651 Alvin Ricken Drive, Pocatello, ID 83201-8046 Phone: 208-282-2179 Fax:
More informationELIZABETH CITY STATE UNIVERSITY Compliance Policies and Procedures
ELIZABETH CITY STATE UNIVERSITY Compliance Policies and Procedures Preamble Elizabeth City State University (ECSU) pursues federal, state and local resources to support teaching, research and community
More informationGenetics Module B, Anchor 3
Genetics Module B, Anchor 3 Key Concepts: - An individual s characteristics are determines by factors that are passed from one parental generation to the next. - During gamete formation, the alleles for
More informationBIOLOGICAL WASTE DISPOSAL (Biohazardous & Anatomical Wastes)
Excerpted from EHS Hazardous Waste and Disposal Guide BIOLOGICAL WASTE DISPOSAL (Biohazardous & Anatomical Wastes) DEFINITION: Biohazardous waste is any waste generated from working in biological or biomedical
More informationGENE CLONING AND RECOMBINANT DNA TECHNOLOGY
GENE CLONING AND RECOMBINANT DNA TECHNOLOGY What is recombinant DNA? DNA from 2 different sources (often from 2 different species) are combined together in vitro. Recombinant DNA forms the basis of cloning.
More informationMolecular Biology And Biotechnology
in Molecular Biology And Biotechnology National Institute of Molecular Biology and Biotechnology College of Science University of the Philippines Diliman, Quezon City 1101 National Institute of Molecular
More informationUCCS Biosafety Management Policy
UCCS Biosafety Management Policy SAFE STORAGE AND HANDLING OF BIOLOGICAL LABORATORY WASTE (For assistance, please contact Environmental Health & Safety) It is the intention of the University of Colorado
More informationAudit and Risk Committee Charter. 1. Membership of the Committee. 2. Administrative matters
Audit and Risk Committee Charter The Audit and Risk Committee (the Committee ) is a Committee of the Board established with the specific powers delegated to it under Clause 8.15 of the Company s Constitution
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Hematology and Blood Banking
Course Curriculum for Master Degree in Medical Laboratory Sciences/Hematology and Blood Banking The Master Degree in Medical Laboratory Sciences /Hematology & Blood Banking, is awarded by the Faculty of
More informationGenetic Technology. Name: Class: Date: Multiple Choice Identify the choice that best completes the statement or answers the question.
Name: Class: Date: Genetic Technology Multiple Choice Identify the choice that best completes the statement or answers the question. 1. An application of using DNA technology to help environmental scientists
More informationOffice of Laboratory Science and Safety
Office of Laboratory Science and Safety Segaran Pillai, Ph.D, SM AAM, SM ASCP Director, Office of Laboratory Science and Safety Office of the Commissioner Office of the Chief Scientist Mission Statement
More informationSTANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA
STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA SOP#: 013.4 Date Issued: 11/00 Date Revised: 9/14 Page 1 of 7 TITLE: SCOPE: RESPONSIBILITY: PURPOSE: All New Animal
More informationGenetics Lecture Notes 7.03 2005. Lectures 1 2
Genetics Lecture Notes 7.03 2005 Lectures 1 2 Lecture 1 We will begin this course with the question: What is a gene? This question will take us four lectures to answer because there are actually several
More informationA GUIDE FOR THE PRINCIPAL INVESTIGATOR Regulatory Obligations and Compliance Tools
Part I Laboratory Health & Safety Responsibilities A GUIDE FOR THE PRINCIPAL INVESTIGATOR Regulatory Obligations and Compliance Tools University of California Santa Cruz Environmental Health and Safety
More informationResponse to Biological Spills in the Laboratory (Intentional or Accidental)
Response to Biological Spills in the Laboratory (Intentional or Accidental) Exposure Management For splash to eyes, mucous membranes, or broken area of the skin Irrigate eyes with clean water, saline or
More informationUniversity of Colorado at Boulder
University of Colorado at Boulder Department of Public Safety Division of Environmental Health and Safety Environmental Health and Safety Center 1000 Regent Drive, 413 UCB Boulder, Colorado 80309-0413
More informationRMM 501 Hazardous Materials Management Systems Including WHMIS Program Page 2 November 2014
RMM 501 Hazardous Materials Management Systems Including WHMIS Program Page 2 3.4 McMaster University RMM #300 Safety Orientation and Training Program 3.5 McMaster University RMM #301 Standard Operating
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
More information1. Program Title Master of Science Program in Biochemistry (International Program)
1 Program Structure and Specification Master of Science Program in Biochemistry (International Program) Curriculum Last Revised in 2012 for Students Entering in Academic Year 2016 -----------------------------------------
More informationrestriction enzymes 350 Home R. Ward: Spring 2001
restriction enzymes 350 Home Restriction Enzymes (endonucleases): molecular scissors that cut DNA Properties of widely used Type II restriction enzymes: recognize a single sequence of bases in dsdna, usually
More informationContact MaryAnn Picard with any questions: maryann_picard@uml.edu (978) 934-3403
Thank you for your interest in utilizing the cutting edge technology M2D2 has to offer with our lab facilities. Please reference the Onboarding step below, which outlines the process to apply as a resident
More informationA CONTENT STANDARD IS NOT MET UNLESS APPLICABLE CHARACTERISTICS OF SCIENCE ARE ALSO ADDRESSED AT THE SAME TIME.
Biology Curriculum The Georgia Performance Standards are designed to provide students with the knowledge and skills for proficiency in science. The Project 2061 s Benchmarks for Science Literacy is used
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
More informationHUMAN GENETIC TESTING PATENTS : ELIGIBILITY AND ENFORCEMENT
HUMAN GENETIC TESTING PATENTS : ELIGIBILITY AND ENFORCEMENT FRENCH APPROACH DENISE HIRSCH HEAD OF IP THE ENVIRONNENT Patentability of living organism was a public debate in France focusing on ethical issues
More informationCompiled and/or written by Amy B. Vento and David R. Gillum
Fact Sheet Describing Recombinant DNA and Elements Utilizing Recombinant DNA Such as Plasmids and Viral Vectors, and the Application of Recombinant DNA Techniques in Molecular Biology Compiled and/or written
More informationCystic Fibrosis Foundation PILOT AND FEASIBILITY AWARD
Cystic Fibrosis Foundation PILOT AND FEASIBILITY AWARD Policies and Guidelines CFF Grants and Contracts Office 6931 Arlington Road Bethesda, MD 20814 (301) 841-2637 grants@cff.org I. PILOT AND FEASIBILITY
More informationAAV specific issues pertaining to vector shedding in gene therapy clinical trials. Samuel Wadsworth Genzyme Corporation
AAV specific issues pertaining to vector shedding in gene therapy clinical trials Samuel Wadsworth Genzyme Corporation Workshop objectives Assess the impact of vector design on shedding (studies) Review
More informationLASER SAFETY MANUAL UNIVERSITY OF KENTUCKY POLICIES AND PROCEDURES FOR LASER USERS REVISED EDITION 2012 ISSUED BY
LASER SAFETY MANUAL UNIVERSITY OF KENTUCKY POLICIES AND PROCEDURES FOR LASER USERS REVISED EDITION 2012 ISSUED BY UNIVERSITY OF KENTUCKY RADIATION SAFETY OFFICE TABLE OF CONTENTS POLICY AND PURPOSE 2 LASER
More informationEvaluation Instrument for Accreditation January 1, 2016
Evaluation Instrument for Accreditation January 1, 2016 Copyright 2002-2014 AAHRPP. All rights reserved. Use of the Evaluation Instrument for Accreditation The Evaluation Instrument for Accreditation is
More informationMedical or Biological Waste: Storage, Treatment, Disposal and Transportation Plan
Medical or Biological Waste: Storage, Treatment, Disposal and Transportation Plan 1. Scope This program covers all departments at Wellesley College who generate medical or biological waste to include Health
More informationPOTENTIAL HAZARD INFORMATION & SIGNATURE SHEET
POTENTIAL HAZARD INFORMATION & SIGNATURE SHEET Scientific research involves exposure to various hazards. When deciding to allow your child to participate in research projects conducted in University of
More informationhttp://www.cdc.gov/od/ohs/biosfty/bmbl4/b4ai.htm Office of Health and Safety (OHS) BMBL Appendix I
Office of Health and Safety (OHS) References BMBL Appendix I Guidelines for Work With Toxins of Biological Origin Biosafety Documents BMBL Table of Contents In recognition of the growing number of microbiological
More information